MTA1 is an indicator of prognosis in Chinese patients with lung adenocarcinoma

BACKGROUND: The predictive role of metastatic tumor antigen 1 (MTA1) expression in lung cancer (LC) is still uncertain. This meta-analysis was performed to clarify the relationship of MTA1 protein expression with the prognosis of LC. METHODS: The PubMed and CNKI databases were searched for clinical studies demonstrating the expression of MTA1 in LC for further review. RESULTS: A total of ten studies comprising 982 patients were included in the meta-analysis according to the predefined selection criteria. Our results indicated that MTA1 overexpression had a significant impact on progression-free survival (PFS) (HR 2.16; 95% CI, 1.62–2.89) and OS (HR 2.38; 95% CI, 1.78–3.19). Heterogeneity was observed (I(2)=34.6%). When the analyses were restricted to adenocarcinoma cases, high expression of MTA1 also predicted poor prognosis (HR 2.14; 95% CI, 1.48–3.08). However, no statistically significant heterogeneity was observed among the studies (I(2)=4.1%). CONCLUSIONS: A high level of MTA1 expression predicts poor survival in Chinese patients with lung adenocarcinoma.